Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 02, 2024 | May 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 02, 2024 · Filed May 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,485.82 |
Ending reported balance
After 2024-05-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-02 · Exercise / conversion · Acquired 29,350 · Balance 33,835.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Row 2 · 2024-05-02 · Sale · Disposed 12,207 · Balance 21,628.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2024-05-02 · Sale · Disposed 17,143 · Balance 4,485.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2024-05-10 | Direct | 0 |
Reported balance
After 2024-05-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-02 · Exercise / conversion · Disposed 29,350 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Living Trust | 4,038,377 |
Reported balance
Holding disclosure · report date 2024-05-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,038,377 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 15,575 | $73.94 | $1,151,615.50 |
DisclosureSEC source: 0001225208-22-011662 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $73.40 to $74.39 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-011662 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,927.82 Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,100 | $74.86 | $306,926.00 |
DisclosureSEC source: 0001225208-22-011662 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,427.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.41 to $75.41 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 200 | $75.47 | $15,094.00 |
DisclosureSEC source: 0001225208-22-011662 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,527.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| November 14, 2022 Filed Nov 15, 2022 00:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-22-011662 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,727.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,375 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · derivative · entry 9 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,625 Underlying: Common Stock · 29,375 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,454,017 Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 14,497 | $82.41 | $1,194,697.77 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F5 · price: This transaction was executed in multiple trades at prices ranging from $81.920 to $82.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,849.82 Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,978 | $83.38 | $248,305.64 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,349.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $82.950 to $83.910. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,800 | $84.64 | $152,352.00 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,327.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $84.020 to $85.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 600 | $85.28 | $51,168.00 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,127.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.070 to $85.775 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2022 Filed Oct 14, 2022 23:10 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-22-010970 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,727.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,375 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 29,375 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,444,517 Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,675 | $84.07 | $1,401,867.25 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $83.50 to $84.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,027.82 Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,100 | $84.66 | $262,446.00 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,527.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.51 to $85.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $85.26 | $8,525.50 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,627.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| September 22, 2022 Filed Sep 22, 2022 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-22-010422 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,727.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,375 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,375 Underlying: Common Stock · 29,375 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,435,017 Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 15,773 | $104.92 | $1,654,903.16 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $104.39 to $105.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,125.82 Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,002 | $104.03 | $416,328.06 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,625.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $103.36 to $104.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 100 | $105.41 | $10,541.00 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,627.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-22-009571 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,727.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,375 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,750 Underlying: Common Stock · 29,375 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,425,517 Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 7,951 | $96.87 | $770,213.37 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,852.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $96.330 to $97.120. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,000 | $94.56 | $567,360.00 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,803.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $94.170 to $95.130. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,924 | $95.89 | $568,052.36 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,803.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $95.315 to $96.310. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 14, 2022 Filed Jul 15, 2022 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-22-008783 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,727.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 29,375 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · derivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,125 Underlying: Common Stock · 29,375 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,416,017 Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,107 | $87.14 | $880,723.98 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $86.640 to $87.610. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,459.82 Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,714 | $86.24 | $579,015.36 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,959.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $85.630 to $86.630. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,054 | $87.92 | $268,507.68 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,673.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $87.645 to $88.510. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 14, 2022 Filed Jun 14, 2022 23:53 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 29,375 | $35.20 | $1,033,903.06 |
DisclosureSEC source: 0001225208-22-008106 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,727.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2022. Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 45,050 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · derivative · entry 11 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,050 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,406,517 Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 13,098 | $94.54 | $1,238,284.92 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,352.82 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $93.890 to $94.890. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,450.82 Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,028 | $95.39 | $1,147,350.92 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,950.82 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $94.900 to $95.900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,700 | $93.41 | $439,027.00 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,978.82 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $92.880 to $93.880. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,724 | $96.12 | $261,830.88 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,678.82 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $95.905 to $96.470. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,402.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 56,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006818 · doc4.xml · derivative · entry 10 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,712 Underlying: Common Stock · 56,831 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.